

# Non-surgical reduction of the myocardial septum

## 1 Guidance

- 1.1 Current evidence on the safety and efficacy of non-surgical reduction of the myocardial septum appears adequate to support the use of the procedure, provided that normal arrangements are in place for consent, audit and clinical governance.
- 1.2 The procedure should only be performed in specialist units by clinicians who have had adequate training in the technique. The British Cardiovascular Intervention Society has agreed to produce standards for training.

## 2 The procedure

### 2.1 Indications

- 2.1.1 Non-surgical reduction of the myocardial septum is used to treat outflow tract obstruction in patients with hypertrophic obstructive cardiomyopathy (HOCM). Patients with HOCM have abnormally thickened heart muscle, which narrows the outflow tract from the left ventricle, often causing chest pain, breathlessness, palpitations and fainting spells. There is an increased risk of sudden death from heart attacks or abnormal heart rhythms.
- 2.1.2 Most patients with HOCM are treated with medication. More invasive treatments may be considered in patients who still get symptoms despite drug treatment. The standard surgical treatment is ventricular septal myotomy-myectomy, using an open surgical technique that requires cardiopulmonary bypass.

### 2.2 Outline of the procedure

- 2.2.1 Non-surgical reduction of the myocardial septum does not require open chest surgery or cardiopulmonary bypass. It involves inserting a catheter into the femoral artery and passing it up into the heart under X-ray control. Alcohol is injected into an artery that supplies blood to the septum. This destroys a part of the muscle in the septum, which then becomes thinner.

### 2.3 Efficacy

- 2.3.1 The studies showed that non-surgical reduction of the myocardial septum is efficacious in the short term. In three non-randomised studies, the mean reduction in gradient across the left ventricular outflow tract (LVOT) ranged from 22 mmHg to 42 mmHg, and compared favourably to the mean reduction in LVOT gradient for open surgery. The studies also reported reduced numbers of patients suffering from severe breathlessness and fainting spells after treatment. There is, however, a lack of long-term follow-up. For more details, refer to the Sources of evidence (see below).
- 2.3.2 The Specialist Advisors considered the procedure to be an established alternative to surgical relief of outflow tract obstruction in patients with HOCM.

# Interventional Procedure Guidance 40

## This guidance is written in the following context:

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to take it fully into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

## 2.4 Safety

- 2.4.1 In the studies, the most commonly reported complication was the need for patients to have a pacemaker implanted permanently because of complete heart block following the procedure. In one non-randomised study of 41 patients, 9 patients (22%) required a permanent pacemaker. The same study reported one procedure-related death. For more details, refer to the Sources of evidence (see below).
- 2.4.2 The Specialist Advisors cited a 10% risk of complete heart block, requiring patients to have a permanent pacemaker implanted after having the procedure. The Advisors considered the procedure to be safe when performed by experienced operators in specialist units with an established interest in HOCM.

## 2.5 Other comments

- 2.5.1 Skilled use of ultrasound is required to identify the blood supply to the hypertrophic myocardium, and thus control the infarct size.
- 2.5.2 Appropriate patient selection is essential.

Andrew Dillon  
Chief Executive  
February 2004

## Information for the Public

NICE has produced information describing its guidance on this procedure for patients, carers and those with a wider interest in healthcare. It explains the nature of the procedure and the decision made, and has been written with patient consent in mind. This information is available, in English and Welsh, from [www.nice.org.uk/IPG40publicinfo](http://www.nice.org.uk/IPG40publicinfo).

## Sources of evidence

The evidence considered by the Interventional Procedures Advisory Committee is described in the following document.

*Interventional procedure overview of non-surgical reduction of myocardial septum*, November 2002

Available from: [www.nice.org.uk/IP018overview](http://www.nice.org.uk/IP018overview)

### Ordering information

Copies of this guidance can be obtained from the NHS Response Line by telephoning 0870 1555 455 and quoting reference number N0435. *Information for the Public* can be obtained by quoting reference number N0436 for the English version and N0437 for a version in English and Welsh.

The distribution list for this guidance is available on the NICE website at URL [www.nice.org.uk/IPG040distributionlist](http://www.nice.org.uk/IPG040distributionlist)

Published by the National Institute for Clinical Excellence, February 2004 ISBN: 1-84257-512-0

© National Institute for Clinical Excellence February 2004. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

**National Institute for Clinical Excellence**

MidCity Place, 71 High Holborn, London WC1V 6NA, website: [www.nice.org.uk](http://www.nice.org.uk)

N0435 1P 20k Feb 04 (ABA)